OmniAb, Inc. (OABI) Q3 2024 Earnings Call Transcript Summary
OmniAb, Inc. (OABI) Q3 2024 Earnings Call Transcript Summary
Operating expenses for Q3 were in line with expectations and are anticipated to be slightly less than total operating expenses in 2023.The following is a summary of the OmniAb, Inc. (OABI) Q3 2024 Earnings Call Transcript:
以下是OmniAb, Inc. (OABI) 2024年第三季度業績會實錄摘要：
Financial Performance:
財務表現:
OmniAb reported Q3 total revenue of $4.2 million, a decrease from $5.5 million in the prior year quarter.
The decrease in revenue was primarily due to lower milestone revenue and ion channel service revenue.
Operating expenses for Q3 were in line with expectations and are anticipated to be slightly less than total operating expenses in 2023.
The net loss for the third quarter of 2024 was $16.4 million, or $0.16 per share.
OmniAb報告第三季度總營業收入420萬美元，較去年同期的550萬美元有所下降。
營業收入下降主要是由於較低的里程碑收入和離子通道服務收入。
第三季度的營業費用符合預期，並預計略低於2023年的總營業費用。
2024年第三季度淨虧損1640萬美元，每股虧損0.16美元。
Business Progress:
業務進展：
OmniAb ended Q3 with 86 active partners and signed three new platform license agreements, including with 92Bio, Memorial Sloan Kettering Cancer Center, and Queen Mary University of London.
Active programs increased to 352, with 39 new program additions and 12 terminations.
OmniAb launched its OmnidAb technology and plans to launch OmniHub for bioinformatics tools and antibody discovery at upcoming scientific conferences.
OmniAb在第三季度結束時擁有86個活躍合作伙伴，並簽署了三項新的平台許可協議，包括與92Bio、紀念斯隆凱特琳癌症中心和倫敦瑪麗女王大學簽署。
活躍項目數量增至352個，新增39個項目並終止12個。
OmniAb推出了其OmnidAb技術，並計劃在即將舉行的科學會議上推出用於生物信息學工具和抗體發現的OmniHub。
Opportunities:
機會：
Continued growth in partner count reflects strong interest in OmniAb's technology and dedication to innovation and collaboration.
New programs and technologies, such as the OmnidAb technology for single-domain antibodies and the upcoming OmniHub platform, provide additional revenue and partnership opportunities.
合作伙伴數量持續增長，反映出對OmniAb技術的濃厚興趣和創新與合作的承諾。
新項目和技術，如用於單域抗體的OmnidAb技術和即將推出的OmniHub平台，爲額外的營業收入和合作機會提供了可能。
Risks:
風險：
Market forces and industry dynamics are contributing to volatility in OmniAb's business, influencing the timing of revenue recognition from milestones.
Partner restructuring and pipeline prioritization could impact expected milestone hits and program advancements.
市場力量和行業動態正在影響OmniAb業務的不穩定性，影響着里程碑的營業收入確認時機。
合作伙伴重組和管線優先級排序可能會影響預期的里程碑實現和項目進展。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
